LinkedIn Linkedin ENDE
Skip to main content
SYNLAB
Press Releases

SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments, and corporates. Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.

SYNLAB AG delisted on 12 July 2024 from Frankfurt Stock Exchange. Information for bond holders can be found here:
 

Bond Holders


Mission | Vision | Value


Our Mission   

We provide actionable diagnostic information for healthy lives and well-being for all.

Our Vision  

Leadership through excellence in service to patients and the medical community with reliable diagnostics and value added.

Our Value  

Passion | Accountability | Customer centricity

 

More

Ad-hoc Releases

Compensation Reports and Declaration of Conformity

 

2023

2022

2021

Compensation Report

25 March 2024
Report

16 March 2023
Report

16 March 2022
Report

Declaration of Conformity with the
German Corporate Governance Code

December 2023
Declaration

December 2022
Declaration

December 2021
Declaration

 

Managers' Transactions

Managers' Transactions (formerly: Directors' Dealings)

 

For questions please refer to:

  +49 89 307602-0
  ir@synlab.com